RxDoctor Payments Data

Lawrence Hitzeman, MD

Internal Medicine · New York, NYNPI 1124248463

Payments from drug & device makers

$82,243in general payments, 2019–2025

Across 230 payments — averaging $357.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$67K
  • Viiv Healthcare Company$14K
  • Janssen Products, LP$336
  • AbbVie$145
  • Novo Nordisk$125
  • Medtronic$103
  • plus $355 from 7 others

What the payments were for

  • Consulting fees$6,5008%
  • Speaking & faculty fees$63,85078%
  • Travel & lodging$5,9367%
  • Food & beverage$5,7107%
  • Education$2470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$82,243 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$125,636
Medicare patients
353
Services billed
1,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala275$1,204,965
SerostimSomatropin28$615,156
DovatoDolutegravir Sodium/Lamivudine117$421,885
DescovyEmtricitabine/Tenofov Alafenam134$315,659
GenvoyaElviteg/Cob/Emtri/Tenof Alafen53$306,743
OdefseyEmtricitab/Rilpiviri/Tenof Ala60$245,509
IsentressRaltegravir Potassium110$235,453
TriumeqAbacavir/Dolutegravir/Lamivudi57$207,353
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf41$183,126
PrezistaDarunavir61$156,067
EliquisApixaban123$137,790
JulucaDolutegravir/Rilpivirine21$87,881
CabenuvaCabotegravir/Rilpivirine11$70,808
JardianceEmpagliflozin72$69,264
TivicayDolutegravir Sodium29$64,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$67,212$1,827,367462 claims
Viiv Healthcare CompanyDovato, Triumeq, Juluca, Cabenuva, Tivicay$13,966$852,117235 claims
MerckIsentress, Januvia, Pifeltro$17$285,080148 claims
Janssen Products, LPSymtuza$336$183,12641 claims
Boehringer IngelheimJardiance$96$69,26472 claims
Novo NordiskOzempic$125$24,58724 claims
Johnson & JohnsonXarelto$103$24,29522 claims
AbbVieRestasis, Norvir$145$18,25433 claims
E.r. Squibb & Sons, L.L.C.Evotaz$101$17,37911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →